Recruiting
Phase 2

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

Sponsor:

Rita Assi

Code:

NCT06484920

Conditions

Relapsed Hodgkin Lymphoma

Refractory Hodgkin Lymphoma

Relapsed Non-Hodgkin Lymphoma

Refractory Non-Hodgkin Lymphoma

B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ATRA

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information